ArTS Archivio della ricerca di Trieste

ZAJA, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.264
EU - Europa 3.001
AS - Asia 2.667
AF - Africa 24
SA - Sud America 14
OC - Oceania 8
Continente sconosciuto - Info sul continente non disponibili 2
Totale 14.980
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.226
SG - Singapore 1.068
PL - Polonia 893
SE - Svezia 868
HK - Hong Kong 753
CN - Cina 622
IT - Italia 364
BG - Bulgaria 268
IE - Irlanda 251
DE - Germania 107
KR - Corea 42
UA - Ucraina 41
VN - Vietnam 38
CA - Canada 34
TR - Turchia 34
IN - India 32
GB - Regno Unito 31
FI - Finlandia 30
CH - Svizzera 27
JP - Giappone 25
FR - Francia 24
RU - Federazione Russa 22
BE - Belgio 20
SN - Senegal 17
ES - Italia 16
IL - Israele 16
AT - Austria 8
AU - Australia 8
NL - Olanda 8
IR - Iran 7
PK - Pakistan 7
BR - Brasile 6
RO - Romania 6
HR - Croazia 5
PE - Perù 5
CZ - Repubblica Ceca 4
LK - Sri Lanka 4
TW - Taiwan 4
BD - Bangladesh 3
DK - Danimarca 3
EG - Egitto 3
MX - Messico 3
A2 - ???statistics.table.value.countryCode.A2??? 2
CL - Cile 2
DZ - Algeria 2
HU - Ungheria 2
JO - Giordania 2
LA - Repubblica Popolare Democratica del Laos 2
LT - Lituania 2
MY - Malesia 2
AE - Emirati Arabi Uniti 1
AR - Argentina 1
AZ - Azerbaigian 1
GE - Georgia 1
ID - Indonesia 1
MQ - Martinica 1
NO - Norvegia 1
PH - Filippine 1
TH - Thailandia 1
TN - Tunisia 1
ZA - Sudafrica 1
Totale 14.980
Salva come PNG Salva come JPEG
Città #
Fairfield 1.597
Singapore 944
Warsaw 883
Ashburn 836
Woodbridge 769
Hong Kong 753
Seattle 660
Houston 652
Wilmington 613
Chandler 596
Cambridge 517
Princeton 478
Ann Arbor 290
Sofia 268
Beijing 266
Dublin 248
Jacksonville 243
Santa Clara 243
Boardman 155
Trieste 144
San Diego 123
Seoul 40
Dong Ket 36
Norwalk 35
Nanjing 25
Redwood City 25
Bremen 21
Helsinki 20
Bern 19
Washington 18
Brussels 17
Dakar 17
Dearborn 17
Jinan 17
Milan 15
Andover 14
Izmir 14
Fremont 13
Shanghai 12
London 11
Rome 11
Toronto 11
Kocaeli 10
Los Angeles 10
Hefei 9
Munich 9
Padova 9
Kochi 8
Monmouth Junction 8
Shenyang 8
Taiyuan 8
Tianjin 8
Udine 8
Krefeld 7
Kunming 7
Pune 7
Redmond 7
San Bartolomeo in Galdo 7
Ardabil 6
Dallas 6
Fuzhou 6
Guangzhou 6
Leawood 6
Lublin 6
Backa 5
Gradisca D'isonzo 5
Hebei 5
Karachi 5
Murcia 5
Phoenix 5
Pignone 5
Vienna 5
Zhengzhou 5
Zurich 5
Augusta 4
Des Moines 4
Frankfurt am Main 4
Hangzhou 4
Islington 4
Kollam 4
Legnaro 4
Montreal 4
Moscow 4
New York 4
Shenzhen 4
Tappahannock 4
Tokyo 4
Venezia 4
Vicenza 4
Antwerpen 3
Basel 3
Casier 3
Changsha 3
Grafing 3
Istanbul 3
Kandana 3
Kitamachi 3
Kobe 3
Lanzhou 3
Laval 3
Totale 11.995
Salva come PNG Salva come JPEG
Nome #
NOTCH1 mutations associate with low CD20 level in chronic lymphocytic leukemia: Evidence for a NOTCH1 mutation-driven epigenetic dysregulation 313
KRAS, NRAS, and BRAF mutations are highly enriched in trisomy 12 chronic lymphocytic leukemia and are associated with shorter treatment-free survival 258
Mutations in the 3' untranslated region (3' UTR) of NOTCH1 are associated with low CD20 expression levels in chronic lymphocytic leukemia 253
Detection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug Nutlin-3: a proposal for clinical application. 176
NOTCH1-mutated chronic lymphocytic leukemia cells are characterized by a MYC-related overexpression of nucleophosmin 1 and ribosome-associated components 172
CD49d is overexpressed by trisomy 12 chronic lymphocytic leukemia cells: evidence for a methylation-dependent regulation mechanism. 161
Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia 160
Recombinant Zoster Vaccine Significantly Reduces the Impact on Quality of Life Caused by Herpes Zoster in Adult Autologous Hematopoietic Stem Cell Transplant Recipients: A Randomized Placebo-Controlled Trial (ZOE-HSCT) 155
Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials 149
The efficacy of lenalidomide combination therapy in heavily pretreated non-Hodgkin lymphoma patients: an Italian observational, multicenter, retrospective study 143
The SIRT1/TP53 axis is activated upon B-cell receptor triggering via miR-132 up-regulation in chronic lymphocytic leukemia cells 138
Persistent CD49d engagement in circulating CLL cells: a role for blood-borne ligands? 137
Treatment for patients with relapsed/refractory mantle cell lymphoma: European-based recommendations 135
A B-cell receptor-related gene signature predicts response to ibrutinib treatment in mantle cell lymphoma cell lines 131
CD49d prevails over the novel recurrent mutations as independent prognosticator of overall survival in chronic lymphocytic leukemia. 129
Interferon-free compared to interferon-based antiviral regimens as first-line therapy for B-cell lymphoproliferative disorders associated with hepatitis C virus infection 124
Rituximab in the treatment of immune thrombocytopenia: What is the role of this agent in 2019? 121
Low-dose rituximab in adult patients with primary immune thrombocytopenia 120
Tapering and discontinuation of thrombopoietin receptor agonists in immune thrombocytopenia: Real-world recommendations 119
Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis 109
Impact of hepatitis C virus infection on clinical features, quality of life and survival of patients with lymphoplasmacytoid lymphoma/immunocytoma 108
Rituximab for the treatment of type II mixed cryoglobulinemia 107
Efficacy of selective B cell Blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells 103
MYC Rearranged Aggressive B-Cell Lymphomas: A Report on 100 Patients of the Fondazione Italiana Linfomi (FIL) 101
Integration of transcriptional and mutational data simplifies the stratification of peripheral T-cell lymphoma 100
Long-term follow-up analysis after rituximab salvage therapy in adult patients with immune thrombocytopenia 96
Incidence, outcome, and risk factors of late-onset noninfectious pulmonary complications after unrelated donor stem cell transplantation 94
Rituximab in a case of cold agglutinin disease 93
ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned 92
Prognostic significance of delayed thrombocytopenia after allogeneic stem cell transplant 92
Successful treatment and FDG-PET/CT monitoring of HHV-6 encephalitis in a non-neutropenic patient: case report and literature review 92
Efficacy and safety of rituximab in type II mixed cryoglobulinemia 90
CHOP-rituximab with pegylated liposomal doxorubicin for the treatment of elderly patients with diffuse large B-cell lymphoma 90
Bendamustine in chronic lymphocytic leukemia: Outcome according to different clinical and biological prognostic factors in the everyday clinical practice 90
Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia 90
Acute hepatic failure as onset of progressive sclerodermatous chronic graft-versus-host disease after donor lymphocyte infusion 89
Bendamustine salvage therapy for T cell neoplasms 87
A diachronic-comparative analysis for the identification of the most powerful prognostic index for localized diffuse large B-cell lymphoma 87
Rituximab in immune thrombocytopenia: gender, age, and response as predictors of long-term response 87
Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: long-term follow-up results 87
NOTCH1 mutational status in chronic lymphocytic leukaemia: Clinical relevance of subclonal mutations and mutation types 87
Lenalidomide monotherapy in heavily pretreated patients with non-Hodgkin lymphoma: an Italian observational multicenter retrospective study in daily clinical practice 85
MYC protein expression scoring and its impact on the prognosis of aggressive B-cell lymphoma patients 83
Impact of clinical data on chest radiography sensitivity in detecting pulmonary abnormalities in immunocompromised patients with suspected pneumonia 83
Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases 82
The genotype of the hepatitis C virus in patients with HCV-related B cell non-Hodgkin's lymphoma 82
Surgical staging in Hodgkin's disease: the role of laparoscopic splenectomy 81
Activity of all-trans-retinoic acid in a case of central nervous system extramedullary relapse of acute promyelocytic leukemia 80
NOTCH1 mutations are associated with high CD49d expression in chronic lymphocytic leukemia: Link between the NOTCH1 and the NF-κ B pathways 80
Adjuvant treatment with cyclosporin A increases the toxicity of chemotherapy for remission induction in acute non-lymphocytic leukemia 80
Dapsone salvage therapy for adult patients with immune thrombocytopenia relapsed or refractory to steroid and rituximab 79
Treatment of refractory chronic GVHD with rituximab: a GITMO study 78
Management of relapsed/refractory mantle cell lymphoma: a review of current therapeutic strategies 78
Venetoclax in combination with hypomethylating agents in previously untreated patients with acute myeloid leukemia ineligible for intensive treatment: a real-life multicenter experience 77
Earlier administration of Rituximab allows higher rate of long-lasting response in adult patients with autoimmune thrombocytopenia 77
MATILDE chemotherapy regimen for primary CNS lymphoma: results at a median follow-up of 12 years 77
Management of immune thrombocytopenia in elderly patients 77
Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection 77
Chromosome aberrations detected by conventional karyotyping using novel mitogens in chronic lymphocytic leukemia with "normal" FISH: correlations with clinicobiologic parameters 76
Long-lasting complete remission of hepatitis C virus (HCV) infection and HCV-associated immunocytoma with alpha-interferon treatment 76
Alternate use of thrombopoietin receptor agonists in adult primary immune thrombocytopenia patients: A retrospective collaborative survey from Italian hematology centers 75
Decreased function of Fas and variations of the perforin gene in adult patients with primary immune thrombocytopenia 75
HSV-1 cutaneous infection in a patient with Hodgkin's lymphoma treated with brentuximab vedotin 74
Meningeal and cerebral involvement in multiple myeloma patients 74
Lamivudine allows completion of chemotherapy in lymphoma patients with hepatitis B reactivation 74
Diagnostic framing of IgM monoclonal gammopathy: Focus on Waldenström macroglobulinemia 74
Updated international consensus report on the investigation and management of primary immune thrombocytopenia 74
Surgical staging in Hodgkin's disease: the role of laparoscopic splenectomy 73
Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenström macroglobulinemia 73
Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: A phase II clinical trial of the fondazione italiana linfomi 73
A Comparison of the Conditioning Regimens BEAM and FEAM for Autologous Hematopoietic Stem Cell Transplantation in Lymphoma: An Observational Study on 1038 Patients From Fondazione Italiana Linfomi 73
Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL 73
Combination of Rituximab, Bendamustine and Cytarabine (R-BAC) for Patients With Mantle Cell Non-Hodgkin's ineligible for intensive regimens or autologous transplantation. Lymphoma Ineligible for Intensive Regimens or Autologous Transplantation 71
Mutational status of IGHV is the most reliable prognostic marker in trisomy 12 chronic lymphocytic leukemia 71
Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics 70
Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura 69
Molecular prediction of durable remission after first-line fludarabinecyclophosphamide-rituximab in chronic lymphocytic leukemia 69
BCL-2 immunohistochemical evaluation in B-cell chronic lymphocytic leukemia and hairy cell leukemia before treatment with fludarabine and 2-chloro-deoxy-adenosine 69
Nocardiosis with favourable clinical outcome in progressive B-chronic lymphocytic leukaemia 68
Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study 68
New drugs and allogeneic hematopoietic stem cell transplantation for hematological malignancies: do they have a role in bridging, consolidating or conditioning transplantation treatment? 67
Meningeal and cerebral involvement in multiple myeloma patients 67
MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas 66
High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial 66
T-cell chimerism and clinical outcome after reduced-intensity conditioning allogeneic stem cell transplantation 65
Brentuximab vedotin in relapsed/refractory Hodgkin's lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials 65
Hepatitis C virus infection (and additional neoplasms) among marginal zone lymphomas 65
Fludarabine, cyclophosphamide and lenalidomide in patients with relapsed/refractory chronic lymphocytic leukemia. A multicenter phase I–II GIMEMA trial 65
Endogenous endophthalmitis following disseminated fungemia due to Fusarium solani in a patient with acute myeloid leukemia 65
Management of Hodgkin lymphoma in the era of brentuximab vedotin: real-world data from five European countries 65
Mycophenolate Mofetil for Immune Thrombocytopenia. Reply 65
B-cell depletion with rituximab as treatment for autoimmune thrombocytopenia 64
Update on the molecular pathogenesis and targeted approaches of mantle cell lymphoma: summary of the 12th annual conference of the European Mantle Cell Lymphoma Network 64
Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin’s lymphoma: evidence from a multicenter, retrospective study 64
Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial 63
The genotype of the hepatitis C virus in patients with HCV-related B cell non-Hodgkin's lymphoma 63
Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia 63
CD38, BCL-2, PD-1 and PD-1L expression in nodal peripheral T-cell lymphoma (PTCL): Possible biomarkers for novel targeted therapies? 62
Alpha-interferon as maintenance drug after initial fludarabine therapy for patients with chronic lymphocytic leukemia and low-grade non-Hodgkin's lymphoma 61
Fludarabine: an active agent in the treatment of previously-treated and untreated low-grade non-Hodgkin's lymphoma 61
Totale 9.399
Salva come PNG Salva come JPEG
Categoria #
all - tutte 63.409
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 63.409
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20203.340 0 0 0 46 217 469 761 557 611 289 183 207
2020/20213.354 195 357 335 398 248 354 181 236 102 333 164 451
2021/20222.370 57 269 64 240 18 77 169 109 312 234 108 713
2022/20232.377 304 268 241 177 246 473 10 225 270 39 89 35
2023/20241.983 87 75 142 51 83 217 335 626 46 36 129 156
2024/20251.921 48 864 946 63 0 0 0 0 0 0 0 0
Totale 15.785